Attovia Therapeutics Inc (ATTO)

$22.79 +0.26 (1.15%)
Market Cap 1.04B
Revenue (ttm) 1.45B
Net Income (ttm) -92.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6.41%
Debt to Equity Ratio 0.00
Volume 175,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 45.65M
Stochastic %K 36%
Beta N/A
Analysts Strong Sell
Price Target $42.20

Company Profile

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 399 5001
Address:
1091 Industrial Road, Suite 310, San Carlos, United States
Merlintrader
Merlintrader Sep. 3 at 12:31 PM
Attovia Therapeutics ($ATTO) Stock Hub 2026: ATTO-1310 Shows Preliminary Clinical Proof of Concept in Itch, Complete Phase 1b Data Expected in Q4 2026, Cash Funded Into 2030 https://www.merlintrader.com/attovia-therapeutics-atto-stock-hub/
0 · Reply
copytheinsider
copytheinsider Aug. 29 at 10:17 AM
$ATTO just went public and insiders piled in fast 👀
0 · Reply
JFais
JFais Aug. 17 at 8:35 PM
$ATTO (NP) Too early-stage for me, but wanted to highlight yet another of the latest biotech IPO's to be performing well out of the gate $XBI As long as this is the trend for newly public co's, bodes well for the sector (vs all the science projects & bio-blowups we saw prior)
0 · Reply
Invescent
Invescent Aug. 14 at 6:29 AM
$ATTO Recent Insider / Institutional Purchases Goldman Sachs / Colin Walsh 585,000 shares @ $17.58 avg $10.285M Redmile Group / Jeremy Green 600,000 shares @ $17.00 $10.20M Frazier Life Sciences XI 588,235 shares @ $17.00 $10.00M venBio Global Strategic Fund IV 382,352 shares @ $17.00 $6.50M Sanofi 300,000 shares @ $17.00 $5.10M TOTAL: ~2.46M shares purchased ~$42.1M in disclosed purchases
0 · Reply
IPOtweet
IPOtweet Aug. 10 at 2:25 PM
IPO Winners & Losers: New Stocks Surge, Biotech Booms, and AI Rallies $BRVE $SPCX $ATTO $FOIL $IPO #IPO https://zpr.io/yd74U46V5uJD
0 · Reply
IPOtweet
IPOtweet Aug. 7 at 10:26 PM
US IPO Weekly Recap: August kicks off with flurry of biotech IPOs $BRVE $LTGO $ATTO $RCBC $BLSM $IPO #IPO https://zpr.io/BtW8qZ4wFgs2
0 · Reply
Latest News on ATTO
Attovia Therapeutics to Participate in Upcoming Investor Conferences

Sep 3, 2026, 4:05 PM EDT - 10 days ago

Attovia Therapeutics to Participate in Upcoming Investor Conferences

Attovia reports Q2 EPS ($4.88), consensus ($4.61)

2026-09-02T20:15:37.000Z - 11 days ago

Attovia reports Q2 EPS ($4.88), consensus ($4.61)

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Sep 2, 2026, 4:05 PM EDT - 11 days ago

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics Quarterly report: Q2 2026

Sep 2, 2026, 8:00 AM EDT - 11 days ago

Attovia Therapeutics Quarterly report: Q2 2026

Attovia Therapeutics Earnings release: Q2 2026

Sep 2, 2026, 8:00 AM EDT - 11 days ago

Attovia Therapeutics Earnings release: Q2 2026

Attovia initiated with an Outperform at LifeSci Capital

2026-08-31T10:25:30.000Z - 13 days ago

Attovia initiated with an Outperform at LifeSci Capital

Attovia initiated with an Outperform at Leerink

2026-08-31T10:25:05.000Z - 13 days ago

Attovia initiated with an Outperform at Leerink

Attovia initiated with a Buy at Citi

2026-08-31T09:15:18.000Z - 14 days ago

Attovia initiated with a Buy at Citi

Attovia initiated with an Overweight at Morgan Stanley

2026-08-31T09:10:05.000Z - 14 days ago

Attovia initiated with an Overweight at Morgan Stanley

Attovia initiated with an Outperform at RBC Capital

2026-08-31T00:25:03.000Z - 14 days ago

Attovia initiated with an Outperform at RBC Capital

Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 6, 2026, 4:05 PM EDT - 5 weeks ago

Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

Aug 6, 2026, 5:57 AM EDT - 5 weeks ago

Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

Attovia opens at $21.00, IPO priced at $17.00

2026-08-05T16:20:17.000Z - 5 weeks ago

Attovia opens at $21.00, IPO priced at $17.00

Attovia indicated to open at $20, IPO priced at $17

2026-08-05T15:45:28.000Z - 5 weeks ago

Attovia indicated to open at $20, IPO priced at $17

Attovia indicated to open at $24, IPO priced at $17

2026-08-05T15:00:27.000Z - 5 weeks ago

Attovia indicated to open at $24, IPO priced at $17

Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

Aug 4, 2026, 8:50 PM EDT - 5 weeks ago

Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

Attovia Therapeutics Registration statement: Registration filing

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

Attovia Therapeutics Registration statement: Registration filing

Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO

Aug 4, 2026, 7:53 AM EDT - 5 weeks ago

Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO

Attovia Therapeutics Registration statement: Registration filing

Jul 29, 2026, 8:00 AM EDT - 6 weeks ago

Attovia Therapeutics Registration statement: Registration filing

Attovia Therapeutics Appoints John W. Smither to Board of Directors

Jul 15, 2026, 8:30 AM EDT - 2 months ago

Attovia Therapeutics Appoints John W. Smither to Board of Directors

Biopharmaceutical company Attovia Therapeutics files for US IPO

Jul 14, 2026, 4:52 PM EDT - 2 months ago

Biopharmaceutical company Attovia Therapeutics files for US IPO

Attovia Therapeutics

Jul 14, 2026, 4:32 PM EDT - 2 months ago

Attovia Therapeutics

Merlintrader
Merlintrader Sep. 3 at 12:31 PM
Attovia Therapeutics ($ATTO) Stock Hub 2026: ATTO-1310 Shows Preliminary Clinical Proof of Concept in Itch, Complete Phase 1b Data Expected in Q4 2026, Cash Funded Into 2030 https://www.merlintrader.com/attovia-therapeutics-atto-stock-hub/
0 · Reply
copytheinsider
copytheinsider Aug. 29 at 10:17 AM
$ATTO just went public and insiders piled in fast 👀
0 · Reply
JFais
JFais Aug. 17 at 8:35 PM
$ATTO (NP) Too early-stage for me, but wanted to highlight yet another of the latest biotech IPO's to be performing well out of the gate $XBI As long as this is the trend for newly public co's, bodes well for the sector (vs all the science projects & bio-blowups we saw prior)
0 · Reply
Invescent
Invescent Aug. 14 at 6:29 AM
$ATTO Recent Insider / Institutional Purchases Goldman Sachs / Colin Walsh 585,000 shares @ $17.58 avg $10.285M Redmile Group / Jeremy Green 600,000 shares @ $17.00 $10.20M Frazier Life Sciences XI 588,235 shares @ $17.00 $10.00M venBio Global Strategic Fund IV 382,352 shares @ $17.00 $6.50M Sanofi 300,000 shares @ $17.00 $5.10M TOTAL: ~2.46M shares purchased ~$42.1M in disclosed purchases
0 · Reply
IPOtweet
IPOtweet Aug. 10 at 2:25 PM
IPO Winners & Losers: New Stocks Surge, Biotech Booms, and AI Rallies $BRVE $SPCX $ATTO $FOIL $IPO #IPO https://zpr.io/yd74U46V5uJD
0 · Reply
IPOtweet
IPOtweet Aug. 7 at 10:26 PM
US IPO Weekly Recap: August kicks off with flurry of biotech IPOs $BRVE $LTGO $ATTO $RCBC $BLSM $IPO #IPO https://zpr.io/BtW8qZ4wFgs2
0 · Reply